Fig. 2

In vivo effects of miR-203 treatment on PyMT mice, started at tumor onset and sustained to the human endpoint. A Schematic of the Dox treatment (in green) schedule in vivo, on miR-203 wild-type or miR-203 knock-in; PyMT mice, from week 10 to the experimental endpoint. B Representative micro-CT images of mice subjected to the Dox treatment (in the figures, “control” indicates miR-203 wild-type; “miR-203” indicates knock-in mice), at 12 weeks of age and at the endpoint (18 weeks of age). C Number of tumors per mouse at the endpoint, in control and miR-203-treated mice. D Final tumor volume of control and miR-203-treated mice. In C, D, data are represented as mean ± s.d. (Number of mice and total number of tumors per group are indicated in the figure.) E Left panel, Representative H&E and Ki67 IHC staining of control and miR-203-treated tumors at the endpoint. Right panel, Violin plot showing the quantification of Ki67 staining, six different fields from three independent tumor samples were analyzed. Scale bar, 500 µm. ****p < 0.0001; ***p < 0.001 (Student’s t test)